Cerus Corporation (CERS)

Market Cap	293.43M
Revenue (ttm)	176.23M
Net Income (ttm)	-19.73M
Shares Out	185.72M
EPS (ttm)	-0.11
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	2,256,038
Open	1.560
Previous Close	1.580
Day's Range	1.550 - 1.640
52-Week Range	1.380 - 2.590
Beta	1.24
Analysts	Buy
Price Target	3.17 (+100.63%)
Earnings Date	Oct 30, 2024

About CERS

Cerus Corporation operates as a biomedical products company. The company focuses on developing and commercializing the INTERCEPT Blood System to enhance blood safety. Its INTERCEPT Blood System, a proprietary technology for controlling biological replication that is designed to reduce blood-borne pathogens in donated blood components intended for transfusion. The company offers INTERCEPT Blood Systems for platelets and plasma, which is designed to inactivate blood-borne pathogens in platelets and plasma donated for transfusion; INTERCEPT Blood ...

• Industry: Medical Devices
• Sector: Healthcare
• IPO Date: Jan 30, 1997
• Employees: 637
• Stock Exchange: NASDAQ
• Ticker Symbol: CERS
• Website: https://www.cerus.com

Financial Performance

In 2023, Cerus's revenue was $156.37 million, a decrease of -3.51% compared to the previous year's $162.05 million. Losses were -$37.49 million, -12.37% less than in 2022.

Analyst Forecast

According to 3 analysts, the average rating for CERS stock is "Buy." The 12-month stock price forecast is $3.17, which is an increase of 100.63% from the latest price.

Price Target

$3.17

(100.63% upside)

Analyst Consensus: Buy